{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T17:37:22Z","timestamp":1777743442254,"version":"3.51.4"},"reference-count":26,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2018,11,9]],"date-time":"2018-11-09T00:00:00Z","timestamp":1541721600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0206688","type":"journal-article","created":{"date-parts":[[2018,11,9]],"date-time":"2018-11-09T19:23:15Z","timestamp":1541791395000},"page":"e0206688","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":17,"title":["Novel models for prediction of benefit and toxicity with FOLFIRINOX treatment of pancreatic cancer using clinically available parameters"],"prefix":"10.1371","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4407-7504","authenticated-orcid":true,"given":"Konstantin","family":"Schlick","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Magnes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lukas","family":"Ratzinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernhard","family":"Jaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lukas","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Melchardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Greil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Egle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2018,11,9]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21387","article-title":"Cancer Statistics, 2017","volume":"67","author":"RL Siegel","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"ref2","first-page":"e205","volume":"36","author":"LM Matrisian","year":"2016"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1002\/1097-0142(19951101)76:9<1671::AID-CNCR2820760926>3.0.CO;2-R","article-title":"The National Cancer Data Base report on pancreatic cancer","volume":"76","author":"JE Niederhuber","year":"1995","journal-title":"Cancer"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer","volume":"364","author":"T Conroy","year":"2011","journal-title":"New England Journal of Medicine"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"DD Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/bjc.2016.45","article-title":"Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer","volume":"114","author":"SM Stein","year":"2016","journal-title":"Br J Cancer"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"MM Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"key":"ref8","unstructured":"US Department of Health and Human Services NIoH, National Cancer Institut (May 28, 2009 (v4.03: June 14, 2010)) Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0."},{"key":"ref9","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","article-title":"Reporting results of cancer treatment","volume":"47","author":"AB Miller","year":"1981","journal-title":"Cancer"},{"key":"ref10","unstructured":"WHO Expert Committee on Physical Status: the Use and Interpretation of Anthropometry (1993: Geneva S, Organization WH (1995) Physical status: the use of and interpretation of anthropometry, report of a WHO expert committee. Geneva: World Health Organization."},{"key":"ref11","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3","article-title":"Index for rating diagnostic tests","volume":"3","author":"WJ Youden","year":"1950","journal-title":"Cancer"},{"key":"ref12","doi-asserted-by":"crossref","DOI":"10.3390\/jcm7010007","article-title":"FOLFIRINOX Chemotherapy in Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis of Retrospective and Phase II Studies","volume":"7","author":"S Thibodeau","year":"2018","journal-title":"J Clin Med"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/bjc.2016.222","article-title":"FOLFIRINOX for advanced pancreatic cancer: the Princess Margaret Cancer Centre experience","volume":"115","author":"MK Chllamma","year":"2016","journal-title":"Br J Cancer"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.cell.2011.11.060","article-title":"Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies","volume":"148","author":"H Haeno","year":"2012","journal-title":"Cell"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1054\/bjoc.1999.1035","article-title":"Decrease of CA 19\u20139 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer","volume":"82","author":"U Halm","year":"2000","journal-title":"Br J Cancer"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1136\/jclinpath-2014-202451","article-title":"Combination of tumour markers CEA and CA19-9 improves the prognostic prediction in patients with pancreatic cancer","volume":"68","author":"D Reitz","year":"2015","journal-title":"J Clin Pathol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1515\/cclm-2014-0447","article-title":"The lymphocyte to monocyte ratio in peripheral blood represents a novel prognostic marker in patients with pancreatic cancer","volume":"53","author":"M Stotz","year":"2015","journal-title":"Clin Chem Lab Med"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/bjc.2013.701","article-title":"Validation of C-reactive protein levels as a prognostic indicator for survival in a large cohort of pancreatic cancer patients","volume":"110","author":"J Szkandera","year":"2014","journal-title":"Br J Cancer"},{"key":"ref19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0078225","article-title":"External validation of the derived neutrophil to lymphocyte ratio as a prognostic marker on a large cohort of pancreatic cancer patients","volume":"8","author":"J Szkandera","year":"2013","journal-title":"PLoS One"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"378","DOI":"10.3322\/caac.21405","article-title":"Obesity and adverse breast cancer risk and outcome: Mechanistic insights and strategies for intervention","volume":"67","author":"M Picon-Ruiz","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-319-48382-5_1","article-title":"The Definition and Prevalence of Obesity and Metabolic Syndrome","volume":"960","author":"A Engin","year":"2017","journal-title":"Adv Exp Med Biol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s13679-017-0263-x","article-title":"Insights into the Link Between Obesity and Cancer","volume":"6","author":"SE Ackerman","year":"2017","journal-title":"Curr Obes Rep"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/nri1937","article-title":"Adipocytokines: mediators linking adipose tissue, inflammation and immunity","volume":"6","author":"H Tilg","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"ref24","first-page":"1049602","article-title":"Positive Effect of Higher Adult Body Mass Index on Overall Survival of Digestive System Cancers Except Pancreatic Cancer: A Systematic Review and Meta-Analysis","volume":"2017","author":"J Han","year":"2017","journal-title":"BioMed Research International"},{"key":"ref25","first-page":"e3305","article-title":"Effect of Body Mass Index on Overall Survival of Pancreatic Cancer","volume":"95","author":"Y-Q Shi","year":"2016","journal-title":"A Meta-Analysis. Medicine"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"6287","DOI":"10.3748\/wjg.v23.i34.6287","article-title":"Body mass index does not affect the survival of pancreatic cancer patients","volume":"23","author":"Q-L Jiang","year":"2017","journal-title":"World Journal of Gastroenterology"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0206688","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T05:01:52Z","timestamp":1589000512000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0206688"}},"subtitle":[],"editor":[{"given":"Aamir","family":"Ahmad","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2018,11,9]]},"references-count":26,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2018,11,9]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0206688","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,9]]}}}